This pharma stock is down

The market is ignoring this pharma veteran. You shouldn't.

Value Research Stock Advisor's next recommendation is coming on Monday, June 23, 2025. Here's why it could be a standout addition to your portfolio.

This pharma stock is down—but not out AI-generated image

“The best investment strategy is the one you can stick with.”
— Morgan Housel, The Psychology of Money

At Value Research Stock Advisor, we have discovered a recurring theme that has worked remarkably well in the pharmaceutical space.

The setup goes like this: A fundamentally strong pharma company faces a temporary setback involving regulatory action. The market, focused only on the immediate, punishes the stock. But the business remains resilient, the long-term story stays intact, and earnings continue to grow. Eventually, the market realises its mistake. A re-rating follows, and patient investors are rewarded.

We have seen this happen before. Two of our best-performing pharma recommendations followed this very pattern. One has grown 8x since our recommendation, and the other has delivered nearly 3x returns.

Our latest recommendation fits this same script.

A setback that is not really a setback

This time, the company has been impacted by a regulatory issue involving one of its drugs. As expected, the stock has been beaten down. But here’s the nuance the market is missing: no drug in its portfolio accounts for more than five per cent of its total sales.

In other words, the company is not dependent on any single product. The so-called setback is just a bump in the road, not a structural threat.

Behind the scenes, the company has been building a far more powerful growth engine.

The quiet transformation of a domestic leader

In India, it is tapping into the explosive rise in chronic and lifestyle-related conditions. Over the last few years, the company has focused its research and marketing efforts on chronic and specialty therapies. It has reorganised its domestic operations into sharper divisions and expanded its sales force to reach deeper into tier-2 and tier-3 towns.

These efforts are already bearing fruit. The company’s India revenue is now growing at a strong double-digit pace.

Meanwhile, in the US, the company is moving beyond plain generics and focusing on complex therapies — injectables, patches, and hard-to-make products. These areas have lower competition and higher profitability. In FY25 alone, the company launched 28 new products in the US, most of them in these complex categories.

The big upside: specialty drugs

While this steady growth would be enough to justify interest, there’s another layer to this story. The company is also developing specialty drugs — a high-margin category involving advanced treatments for chronic, rare, or life-threatening conditions.

Specialty drugs are complex to manufacture and require deep expertise, which limits competition. They also offer significantly higher returns. Our upcoming recommendation already has two such drugs in late-stage development, opening the door to a strong pipeline-driven re-rating.